Document is current
Any future updates will be listed below
-
Authors
Deligne, Clémence
Hachani, Johan
Duban-Deweer, Sophie
Meignan, Samuel
Leblond, Pierre
Carcaboso, Angel M.
Sano, Yasuteru
Shimizu, Fumitaka
Kanda, Takashi
Gosselet, Fabien
Dehouck, Marie-Pierre
Mysiorek, Caroline
-
Funding
Funding for this research was provided by:
'Conseil régional du Nord-Pas-de-Calais'
European Regional Development Fund
Association Cassandra contre la leucémie
Société Française de lutte contre les cancers et les leucémies de l'enfant et de l'adolescent
Association l'étoile de Martin
- License Information
-
More Information
Article History
Received: 21 February 2020
Accepted: 23 May 2020
First Online: 2 June 2020
Ethics approval and consent to participate
: Human pericytes are from the cell line named HBPCT and were provided by Professor Takashi Kanda’s group from Yamagushi University (Japan). The study protocol was approved by local ethic committee and conducted in accordance with the declaration of Helsinki, as amended in Somerset West in 1996 [CitationRef removed].The collection and use of CD34<sup>+</sup> -stem cells derived from cord blood has been approved since 2011 by the French ministry (CODECOH 2011-1321). These cells were harvested thanks to an agreement established between the hospital of Béthune and University of Artois. Informed consents were obtained from the families before starting the study.Patient-derived cells were obtained under an Institutional Review Board-approved protocol and with written informed consent (M-1608-C) at Hospital Sant Joan de Deu Barcelona, Spain.
: Not applicable.
: The authors declare that they have no competing interests.
